BiotechTube

Alkaline Phosphatase + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sepsis

Conditions

Sepsis, Multiple Organ Dysfunction Syndrome

Trial Timeline

Sep 1, 2004 → Mar 1, 2006

NCT ID
NCT00430859

About Alkaline Phosphatase + Placebo

Alkaline Phosphatase + Placebo is a phase 2 stage product being developed by AM-Pharma for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00430859. Target conditions include Sepsis, Multiple Organ Dysfunction Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00430859Phase 2Completed

Competing Products

20 competing products in Sepsis

See all competitors
ProductCompanyStageHype Score
Drotrecogin alfa (activated)Eli LillyPhase 2
52
MeropenemPfizerApproved
84
ImipenemMerckApproved
85
CefiderocolShionogiPhase 1
33
eritoran tetrasodium + PlaceboEisaiPhase 3
77
E5564EisaiPhase 2
52
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin Alfa (activated)Eli LillyApproved
85
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
sPLA2 InhibitorEli LillyPhase 1/2
41
Drotrecogin alfa (activated)Eli LillyApproved
85
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
AZD9773 (CytoFab)AstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD4144 + PlaceboAstraZenecaPhase 2
52

Other Products from AM-Pharma

Recombinant human alkaline phosphatasePhase 3
69
Ilofotase alfa + PlaceboPhase 2
44
recAPPhase 2
44
Placebo + BIAPPhase 2
44
bovine intestinal alkaline phosphatase (BIAP)Phase 2
44